
Herantis Pharma - Soon again a (stronger) clinical company

Redeye revisits its view of Herantis in the wake of the company's shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDFN that allows for non-invasive administration. We slightly raise our base case to SEK 24 per share (22) and expect Herantis to take the important step back into the clinic now in H1 2023.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Herantis Pharma - Soon again a \(stronger\) clinical company](#)